Who is contraindicated in using Acemini?

Asciminib (Asciminib) is a new BCR-ABL inhibitor for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) patients in the chronic phase, especially those who are resistant or intolerant to previous generations of tyrosine kinase inhibitors (TKIs), have demonstrated unique efficacy. As a new generation of targeted drugs after STI571 (imatinib), it has higher targeting and lower off-target effects by selectively inhibiting the "myristoyl" site of the BCR-ABL1 fusion protein. However, despite its outstanding efficacy, aximini is not suitable for use by all patient groups. Some groups have contraindications or need to be carefully evaluated before use.

First, patients who are known to be allergic to the active ingredient of Aceminid or any of its excipients are strictly prohibited from using this drug. Allergic reactions may include severe symptoms such as rash, itching, difficulty breathing, swelling of the throat, edema of the face or lips. Once the patient has a clear history of allergy to similar drugs in the past, the risk should be thoroughly assessed before making a decision. If the above allergic symptoms occur, the medication should be stopped immediately and emergency treatment should be provided. In addition, aceminib is not recommended for use in children or adolescent patients. There is currently insufficient clinical trial data in this population, and safety and efficacy have not been clearly confirmed.

Secondly, pregnant and lactating women are high-risk groups for drug use. Aceminid has been shown to be embryotoxic in animal studies and may cause harm to the fetus, so the drug is contraindicated during pregnancy; female patients should take effective contraceptive measures during use and wait at least one week after stopping the drug before trying to get pregnant again. At the same time, it is unclear whether Aceminib is excreted into newborns through breast milk. For safety reasons, lactating women should avoid breastfeeding while taking the drug to prevent potential adverse effects on the baby.

Third, for patients with severe liver or renal impairment, the metabolism and excretion pathways of aceminib may be affected, causing drug accumulation in the body and increasing the risk of toxic side effects. Although no obvious need for dose adjustment has been observed in patients with mild to moderate hepatic and renal insufficiency, for patients with severe injuries, it is recommended to use it with caution under close monitoring and adjust the dose if necessary. In particular, patients who use strong inhibitors or inducers of CYP3A4 in combination should pay attention to the risk of drug interactions and may need to adjust the dosage or replace the appropriate drug combination.

In addition, patients who are receiving antiarrhythmic drug treatment or who have severe heart disease (such as prolonged QT interval, arrhythmia, etc.) should also use Asiminib with caution. Although this drug carries a lower risk of QT prolongation than some traditional TKI drugs, it may increase the risk of arrhythmias in patients with a history of underlying heart disease or electrolyte abnormalities (eg, hypokalemia, hypomagnesemia). Regular monitoring of electrocardiogram and electrolyte levels is recommended before administration and during treatment.

In general, aceminib, as a new generation of targeted therapy drugs, has shown good efficacy and tolerability in some patients with chronic myelogenous leukemia, and is especially suitable for patients who have failed treatment with previous generations of TKI drugs. However, it is not suitable for everyone. People who are allergic to drug ingredients, pregnant and lactating women, patients with severe liver and kidney dysfunction, and individuals with severe heart disease should carefully evaluate whether to use it. During the actual treatment process, experienced hematology oncologists should conduct detailed disease assessment and formulate individualized medication plans to ensure safe medication and maximize treatment effects. If the patient plans to use it for a long time, it is recommended that blood, liver and kidney function, electrolytes and electrocardiogram be monitored regularly to ensure health management during the medication.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib